27 ms·
Goldman Sachs questions whether curing patients is a sustainable business model
- walkingolof 9y agoThats why "we the people" need to have large part in developing new drugs and the care of people, this is nothing that can be left to the "market" in some hope that it will "work out".
- emiliobumachar 9y agoGood idea, but it takes a lot of cash.
- andybak 9y agoSo do many things not provided adequately by the market.
- wiz21c 9y agoOnce it is in the public hands, it allows for democratic prioritization of the cash (do we need more solar energy or more cures ?).
- Kalounji 9y agoI like to think we need both
- qwbsdfg 9y agoAlthough it might take less cash if only the people actually doing the research needed to get paid. If the patent lawyers, the investment bank analysts writing these reports, and the likes of Martin Shkreli also need to eat everyday that could potentially be inflating the cost.
- hollander 9y agoAnd that's why God invented taxes. But then the US invented their own gods, who don't have to pay tax.
- alimw 9y agoIn many countries including mine, it is the state that pays into drugs companies anyway.
- PeterStuer 9y agoDepends what you mean. 'Cash' as in a 'fiduciary currency' is just a relative prioritization mechanism. 'We the People' should never be able to run out of 'cash' as we ca always just print more. In fact, 'we' have been doing this perpetually at high volume for some time. It is just that 'we' seem to prefer giving it away to select shareholders rather than to fund public beneficial goods or research.
- sjtgraham 9y agoThere is nothing to say the market won't solve problems. Innovations like Gilead's are inevitable. A cure might make less money than chronic treatment, but once a cure exists nobody is buying the treatment. It's rational to develop the cure if you want returns.
- xg15 9y agoIf your ultimate goal is sustainable profit, it would be rational to not even look for a cure at all. As long as there is no practically usable permanent cure, everyone has a stable source of revenue from chronic treatment solutions. Once anyone develops one, the chronic treatment would become significantly less attractive (as you say), so revenue would become less predictable for all parties, including the party that developed the cure.
- sjtgraham 9y ago> If your ultimate goal is sustainable profit, it would be rational to not even look for a cure at all. If you have a monopoly.
- xg15 9y agoIt's enough if you already have a sustainable business selling chronic treatments. Which I think would be likely for the kind of companies that have enough resources to be able to research a permanent cure at all.
- dmurray 9y agoAll possible pharmaceutical innovations are not "inevitable", at least not in any given time frame. It may be that pharma companies know which R&D approaches have a chance of producing a permanent cure, and which ones are more likely to result in a chronic treatment, and they focus their efforts on the former.
- refurb 9y agoYeah, no. You wouldn't have only 1 out of 100 drugs actually making it to market if companies knew which ones would work and which ones wouldn't.
- AlexandrB 9y agoTaxpayers already funds at least a third of drug research [1][2]. Plus the fundamental science research that makes more advanced drugs possible comes out of public universities. [1] https://www.thebalance.com/who-funds-biomedical-research-2663193 https://www.thebalance.com/who-funds-biomedical-research-266... [2] https://other98.com/taxpayers-fund-pharma-research-development/ https://other98.com/taxpayers-fund-pharma-research-developme...
- ekianjo 9y agoYou dont seem to be aware that public universities are already heavily involved in drug development. Looking at the facts is helpful before building a narrative.
- refurb 9y agoI would rephrase that to "basic science that could lead to drug discovery". Public universities can do some initial poking around, but are utterly incapable of actually developing a drug. They've tried and failed many times.
- refurb 9y agoYet we have a ton of breakthrough drugs coming to market, most of which were created by private companies.
- quincunx 9y agoIn this sense gene therapy is "disruptive innovation" in the Clayton M Christensen sense of the word: the incumbents cannot pursue the strategy as doing so eats into their profits. Does it take smaller, independent, outfits to pursue this?
- emiliobumachar 9y agoI agree that, if one-shots get to be profitable at all, incumbents cannot smother them for being less profitable than continuous treatment. Somebody else will do it. The problem is if searching for one-shots gets to be unprofitable altogether.
- dschuetz 9y agoA healthy person is bad for pharmaceutical business and doctors, yet very good for health and life insurances.
- pintxo 9y agoNot sure about that. Insurances require a certain level of "damage" probability, else no one would get insurance in the first place. If you could cure any illness with a $5 pill, I'd guess no one would get health insurance. This is somewhat different for life insurances, as you could still be run over by a (self-driving) car and die.
- Broken_Hippo 9y ago" If you could cure any illness with a $5 pill, I'd guess no one would get health insurance." It is highly unlikely we'll ever get there, especially for genetic disorders and things like that. But who knows. Nevertheless, people will still get run over by a car and be injured, along with a multitude of other, very common accidents. Of course there would still be insurance. Besides, a good amount of insurance in the world is government-funded. (non-us countries, medicaid, subsidies for private care). Another portion is at least partially paid by employers. These folks don't need the certain level of "damage probability". Employers get an extra bonus with decreased absenteeism, and they might possibly be able to stop paying for insurance altogether.
- pantalaimon 9y agoYou could still get run over by a car, self driving or not, and not die but just break your legs, so you'd still need insurance. Actually you need it more than when you'd die if you don't have any dependents.
- emiliobumachar 9y agoThis is one of the downsides of mobbing, shaming and regulating away outrageous prices. If pharma companies can't charge you in the ballpark of a lifetime's earnings for a one-shot, one-shots will be less compelling to them compared with treatments you have to take twice a day for the rest of your life.
- watwut 9y agoThat assumes monopoly. Competition should solve that.
- andybak 9y agoRemembering basic human moral values might help as well.
- oceanman888 9y agoWhich is usually destroyed by competition.
- watwut 9y agoThe trouble is that those who remember those basic values in more complex competitive environments tend to loose competition against those who dont. Not always, but often enough.
- emiliobumachar 9y agoI don't develop cures for diseases at all. Is this moral? If I may go out on a limb and speculate, you don't develop cures for diseases at all either. Is this moral? If someone is going to dedicate their careers to searching for cures to diseases, but only if they can earn a competitive salary doing so, are they more or less moral than us? For the equivalent case for investment, start with "I don't pay people to search for cures to diseases at all. Is that moral?"
- PeterStuer 9y ago
- javajosh 9y agoWait a sec, Gilead made $12.5B in 2015, $4B this year, on a single drug, and that's not enough? Gosh, I remember when $16.5B was a lot of money.
- FranzFerdiNaN 9y agoWelcome to capitalism, where its never enough to please shareholders and we require unlimited growth on a limited world.
- perseiden 9y agoBringing new drugs to markets is expensive: https://en.wikipedia.org/wiki/Cost_of_drug_development https://en.wikipedia.org/wiki/Cost_of_drug_development (These costs include the other 90% of drugs that have probably failed at some development stage)
- lultimouomo 9y agoSo assuming Gilead spent per drug 10% more than the company that spent more in that list, they recovered the whole development cost in a single year. Most industries don't come even close to that.
- lotsofpulp 9y agoDrugs that have an impact like their Hep C treatment don't come around every year, or even every decade. It's almost a lottery.
- wffurr 9y agoTheir hepC treatment is $84,000. And also somehow not profitable enough. There is also now a $300 generic.
- fiiv 9y agoI think perhaps this article's headline is a bit click-baity and it riles up people. Understandable. I also felt this way. But then I read further. The report cited in the article suggests that companies should focus on treatments for things like common cancers, which has a renewable pool of patients. It also suggests diversifying the portfolio of cures. It does not say companies should not bother with curing Hep C like illnesses since there's no money in it.
- shardis 9y agoIt does not say "companies should not bother with curing Hep C like illnesses since there's no money in it." Critical reading skills and leaving out strawmen/non-existent arguments like "there's no money in it" are required.
- fiiv 9y agoWhat exactly about my statement was a non-existent argument? The title is "Is curing patients a sustainable business model?" A non-sustainable business model cannot sustain a business by definition, therefore there is no money in it.
- PeterStuer 9y agoThe 'ideal' drug from a business point of view not only not cures the patient long term, it offer a short term mitigation while increasing the risk on relapse and thus future recurring consumption of the treatment. At the same time it can be IP protected to block alternatives and has an insured third party collective payment coverage to guard against the treated running out of funds to afford the perpetual dependency. This realization goes beyond medicine, and is key to understanding why we live in an 'economy' that produces masses of landfill junk while our technology and manufacturing processes keep on improving.
- xg15 9y agoThis. I'd go further and say that a system where innovation is driven by profit is good at perpetually managing problems but very bad at actually getting rid of them.
- PeterStuer 9y agoIf you dig even further, you will find things like 'unhappy people consume more as they try to buy their way out of misery'. Now of course you don't directly sell unhappiness, but you can sell goods of which the consumption benefits the individual that consumes it, but deteriorates the world a little bit for everyone as a result. A car is a perfect example. Great benefit to the buyer, but through noise, pollution, taking up space etc. a bit of a nuisance to all others and making them more likely to also consume a car so as to at least participate in the benefits. This ends up in a situation where everyone gets locked into a net negative system where individual escape (dumping your own car) just makes you worse of as you just forego the individual benefit without any perceptual change in the collective negatives.
- reificator 9y agoI find a motorcycle with lots of storage to be a nice compromise. Cheaper and more fun too. Of course you do need to take a safety course and be aware of the dangers, but at least people acknowledge their danger. Cars somehow get a collective free pass despite their astronomical death tally.
- gpvos 9y agoThe story goes that in China, doctors used to be paid for keeping you healthy. When you got sick, they didn't get any money anymore. This sounds to me like a system with the proper incentives.
- polskibus 9y agoBy that logic, developer should not be paid if there is a bug in the systems. Besides formal methods that is always the case.
- nabla9 9y agoWith subscription model bugs don't generate income.
- algo646464 9y agoIsn't this just like paying insurance premiums ? Whenever you are sick, the doctor / insurance company loses money curing you.
- gpvos 9y agoIt's similar, but it wouldn't be profitable anymore for doctors to prescribe more medicines or other treatments. Probably the doctors would need to take out insurance instead of the patients.
- cousin_it 9y agoHealthy people are less willing to pay :-(
- cornholio 9y agoSure it is. Gilead made 100 billion dollars curring Hep-C with seed research investments that were probably much less than 1 billion. So as long as this strong differential and potential for profit exists, drug companies feel competitive pressure to produce better treatments, irrespective of the fact that "milking" the pathology would yield them trillions collectively. It's effectively a "tragedy of the commons" of sorts: a single company trying to capture more of the market ruins profits for everybody else by finding a cure; behold, the magic of the free market. They can only escape it by entering non-compete agreements and collectively agreeing not to inovate, a substantial claim that requires substantial evidence.
- xg15 9y agoIt would still require that the company that develops the cure could make more profit off it than it would make with chronic treatments. So if you went purely for profit, you could only develop a cure if: - you could price it higher than the price of the chronic therapy over the full lifetime of a patient. or - you could sell it to more patients than you could have sold the chronic treatment. A lot more, because every patient will only buy the cure once. So even then the incentives would probably lead do driving the price of drugs up significantly. You'd also still have no incentive to actually eradicate a disease.
- cornholio 9y agoYou make a case for shorter patents, that would encourage rapid innovation and and short term profit.
- mft_ 9y agoDrug development is really hard - the odds are stacked against you. Any successful drug with half a business case will be launched - no company can afford to be picky about cure vs. chronic treatment - there just aren't that many successful drug discoveries to enable it.
- deleted 9y ago[deleted]
- anovikov 9y agoIn theory, market will drive things so the cost of one-shot cure will become equal to the capitalized cost of life-long therapy. Either by making the former more expensive, or the latter cheaper. Until the latter becomes a direct money loser.
- fwdpropaganda 9y agoIn theory, theory coincides with practice. In practice, it doesn't. I've long been of the opinion that "free market fundamentalists" are more than anything intellectually lazy people. EDIT: Just to be clear, I'm not attacking you personally. I wouldn't think that a single post on HN sums up the entire thought process of a person, obviously. But that are people for which that observation is entirely applicable.
- koolba 9y ago> But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. I hope for the sake of all humanity that nobody discussed addressing this particular problem directly.
- jimjimjim 9y agothis is why can't have nice things. why doesn't goldman sachs just grow humans and harvest their organs?
- chopin 9y agoHow do you know they don't?
- draugadrotten 9y agoIs harvesting human organs a sustainable business model?
- croon 9y agoAs long as you don't cure other people (with money) and they keep needing new organs, sure.
- atonse 9y agoBecause apparently these humans wouldn't be a recurring revenue of organs. Unfortunately the humans have to die once you harvest their organs. So you'd have to start over. Damn! /s
- hycaria 9y agoNo need for that. Transplants already insure a lifelong dependance on pills.
- userbinator 9y agoEssentially planned obolescence applied to health. Rather unsettling.
- perpetualcrayon 9y agoI wonder if diseases are patentable. That would probably be a hugely profitable market. If a company obtained the patent on the disease they'd almost certainly be the first to market with a patent for the cure.
- scotchmi_st 9y agoSince we're discussing nationalisation of drug development, one more less extreme idea that I think needs more air-time: The creation of government-issued prizes for drug discovery. Here's how it goes- Government X issues a prize of $10B to whichever company comes up with a new drug for, say, blood pressure. (10B being about as much as a company would get in revenue for a blockbuster drug.) Companies submit their drugs, which are then tested independently (see http://www.alltrials.net/ http://www.alltrials.net/ if you want to know why that's important), and if they are found to have passed the requirements in a strictly yes/no manner, they get the money. The IP for the drug then passes to the government, which can then manufacture and sell it at generic rates. Like everything there are down-sides to this method, but it would sidestep a lot of the issues around companies' incentive alignment with healthcare.
- Proven 9y agoOf course it’s not in the fascist Obamacare and single payer model widespread in the West. The profitable model is to work with the state to milk the taxpayer.
- cs702 9y ago...And there you have it, in seven crisp words: a succinct explanation of why and how "health-care" becomes "health-exploitation" when it is primarily or exclusively a profit-seeking endeavor. In theory, competitors would step in with cheaper, faster cures, preventing the exploitation of patients. In reality, many if not most patients find themselves at the mercy of medical offices and hospitals which are themselves seeking to maximize profit and therefore have strong financial incentives to prefer expensive, ongoing treatments over cheap, fast cures.
- phkahler 9y agoWhen you're a business person or a researcher you want to find the big thing that's going to fund your retirement. When you're an engineer you make a career out of building thing after thing. I think this is similar to the difference between US companies and Chinese companies. In the US they want to develop a product and ride that wave for as long as possible, while in China they produce one item and quickly move on to producing the next one in a never ending cycle. This is also why US companies care so much about IP, they want to do something once and retire. One could even frame it as a form of entitlement ;-) Having said that, I do want people who solve major problems to be reasonably compensated. I'm not sure what that looks like.
- smoyer 9y agoIf you're in medicine, you should be more concerned with improving the human condition. I think that most doctors truly want to help others, and we obviously need support companies like drug manufacturers. But there's a huge industry built up around maximizing profits in other ways - I'm not sure how this can be reconciled.
- buserror 9y agoThe health industry has no reason to cure patients. On the contrary, they have reasons to create new patients. And it's across the board. I tell myself exactly that when I look at my toothbrush. A toothbrush lasts about ~3 weeks before needing replacing. I'm sure someone in the industry will tell me that it's because it's made of unobtainium unicorn hair specially designed to make my teeth whiter and all that. I also have a another plastic brush to clean my shotguns of all things (I do a lot of clay pigeon shooting) -- the construction is identical to a toothbrush, just perhaps a tad bigger. Doesn't have the fancy colored handle. Now the brush I'm currently using I've been using for 3 years and the brush is still pretty much pristine, after being used to generously scrub bits of sharp, grim metal once or twice a week. Hmmm... How does that work? Better unicorns? Well, think about it, everyone is changing toothbrush on a monthly basis, that is a huge revenue. Even reducing the lifetime of a toothbrush by 5% would increase the number of brushes sold by a huge amount. All the while, it creates fantastic amount of plastic waste. Fancy packaging and 100% plastic, possibly not even all recyclable.
- dghf 9y ago> I also have a another plastic brush to clean my shotguns of all things (I do a lot of clay pigeon shooting) -- the construction is identical to a toothbrush, just perhaps a tad bigger. Is it, though? Are the bristles made of the same material, for example? I'm guessing that bristles tough enough to scrub metal would not be the best things to use on your teeth and gums.
- stronglikedan 9y agoUnless you like the taste of copper.
- no_u_idiot 9y agoThis is only true for a single company in isolation. Any company making their products worse (whether it's healthcare or something else) will soon be replaced by someone doing it better. As such, any company not producing or selling viable cures for diseases will quickly lose a lot of money to a new company that sells those cures. In practice, this works more or less well depending on which country on earth you are in. But your statement that the health industry has no reason to cure patients is wrong basically everywhere and idiotic at best.
- dingo_bat 9y agoThis is the phase where capitalism turns evil. The mere act of thinking like this is a crime. I hope these people don't suffer from a degenerative disease in their old age, or they will quickly understand their folly.
- dynofuz 9y agoThe industry is being defined too narrow. The full industry includes insurers. Insurers have every reason to cure patients. Cured patients live longer. The longer you live the more years you pay premiums. The more premiums the higher your profits. So insurance is incenivized to put the money in the hands of those who cure rather than those who require insurance to fork up a fixed amount on an ongoing basis.
- sauwan 9y agoDo insurance companies really have this incentive? You can (and probably will) shop around and find a new insurer within a few years.
- dynofuz 9y agoyes youll shop around for the one that'll keep you alive the longest
- danans 9y ago> The longer you live the more years you pay premiums. The more premiums the higher your profits. The longer you live, the more that the cost of your medical care exceeds the premiums that you pay, because the body naturally starts to fail, most acutely and expensively, toward the end of life. This is a big reason why the ACA individual mandate existed, because there is little incentive to pay for care for those who are expensive to care for if healthier people aren't part of the system. It also demonstrates to why for-profit incentives don't work very well for health insurance at a national scale.
- mariodiana 9y agoI encourage people to read (or re-read) this Ars Technica article, especially the second to last paragraph (the one that begins: "To get around the sustainability issue overall[…]") and put your prejudices aside when you do so. There is nothing "broken" about the pharmaceutical industry being described here. The Goldman guy's opinion is that the industry should focus on treating the conditions that affect the greatest number of people, double down on innovation, and turn their focus towards improving the lives of the elderly—which we're all counting on being, once the promise of gene therapy cures the maladies younger and middle aged people suffer from. Oh, the horror!
- solatic 9y agoThe difference between a one-shot cure and a chronic treatment is that the former is sold to customers and the latter turns customers into exploitable assets. If I own a cow, and I milk the cow for all the cow is worth so that I can sell the cow's milk in the market, is the cow my "customer"? Because I give the cow feed and a barn in exchange, whatever it needs so that it can keep giving me milk? A free market works when players have information symmetry and can make free decisions of sound mind. We otherwise resort to regulation, for example to rein in natural monopolies. Regarding chronic treatments, there's nothing the government can do (within this narrow focus) to reduce demand - but the government can set the rules. Specifically, the government can regulate that pharmaceutical companies must balance their research spending between chronic treatments and one-shot cures, rather than going all-in on chronic treatments. The government can set a lifetime cap on revenue from an individual patient for a given drug, such a cap being formulated on the basis of the cost of development and the number of expected patients (i.e. market size - larger markets will have more patients and a lower cap per patient needed to recoup the cost of development), with production guarantees (since the per-unit cost of doses is trivial) for after the lifetime cap is reached. Indeed, such a production guarantee could be met with a publicly-owned-and-funded company tasked with producing generic versions of drugs for patients who have hit their lifetime cap - essentially, a generic drug company prohibited from selling to customers who haven't proven that they have paid more than the lifetime cap, which produces generic versions of drugs still protected under patent, which is now re-defined not as the exclusive right to manufacture but the exclusive right to manufacture and sell without restriction.
- jovial_cavalier 9y agoYour solution is needlessly complicated and overreaching. How about you just make it illegal for doctors (as in the people who actually write the prescriptions) to interact in any way with pharmaceuticals companies? Outside, of course, of simply reading specifications on drugs and seeing what they do. If the people who administer the care have their incentive disconnected from the amount of time the patient spends in treatment, that seems to solve the problem.
- deleted 9y ago[deleted]
- jimhefferon 9y agoRest of us ask, "Is having such people sustainable in out society?"
- pressurefree 9y agoif it aint broke, dont fucking fix it. im talking to you "dev dev dev" faggots.
- dang 9y agoCould you please stop posting unsubstantive comments to Hacker News? https://news.ycombinator.com/newsguidelines.html https://news.ycombinator.com/newsguidelines.html
- dsschnau 9y agoNATIONALIZE HEALTHCARE
- MistahKoala 9y agoWhat a depressing way to spin what are otherwise reasonable questions and comments seemingly addressed by the report. Just as depressing is to see that a microbiology PhD is making her living by recycling clickbait content written by someone else (Mole's article is more or less a facsimile of the original CNBC article).
- WhompingWindows 9y agoI think there's a potential policy play in this. There is already a class of drugs, known as orphan drugs, which are targeted to rarer diseases that currently have no gold standard treatment. Companies are incentivized by the US FDA to make drugs for these conditions. Maybe the FDA could also make a policy space for "cure incentives" which would provide additional economic benefits to companies willing to make drugs or protocols which attempt to cure disease.
- deleted 9y ago[deleted]
- fricat1ve 9y agoI found this comment unintentionally hilarious.
- nfriedly 9y agoI wonder if insurance companies do anything towards funding cheap "unsustainable" cures? Seems like it'd have a high ROI for them.
- teddyh 9y agoCompanies don’t actually want profit if it would also benefit every competitor equally. A cure for a disease would benefit all insurance companies, so there is no competitive advantage for an insurance company to develop one.
- nfriedly 9y agoYea, good point. I can imagine ways where it works out well (e.g. the insurer that found the cheap cure patents it and charges some expensive price that's still significantly cheaper than a lifetime of non-curing treatments. Everybody wins, but the insurance company that owns the cure wins the most.)
- teddyh 9y agoIf they did that, they would no longer be an insurance provider, but a pharmaceutical company, and at that point there’s no reason to develop cures when short term mitigations are even more profitable.
- padobson 9y agoThis is just bad business, only particularly egregious because it's in healthcare. No great product mind I've ever studied sacrificed making a great product for a more profitable, adequate product. In the long run, the company that makes the best product always wins. Apple was never worried about cannibalizing the iPod to make a better product in the iPhone. You won't find anything in Amazon's leadership principles[0] that could justify this kind of thinking. Even Wal-Mart, after pressuring their suppliers for lower costs, doesn't keep the difference as profits. They push their prices lower and build trust with the customer. Curing patients is absolutely a sustainable business model, and only the most small minded, short-sighted Wall Street suit would think it isn't. [0]https://www.amazon.jobs/principles https://www.amazon.jobs/principles
- crawfordcomeaux 9y agoSystemic mechanisms in the culture of capitalism are in direct conflict with the Hippocratic oath. Capitalism breeds inequality and so it does harm.
- ako 9y agoAnd that is why healthcare should not be a for profit business.
- paulie_a 9y agoThe next time Goldman Sachs has to be bailed out they shouldn't be cured.
- Bartweiss 9y ago...are they wrong about this? It feels very much like a "shoot the messenger" response. GS isn't saying this is a good outcome, or even that gene therapy companies don't deserve investment. They're just claiming that the existing revenue model for drug companies won't lead to success here. The obvious defense of that claim is "if it's true, saying it isn't a sin". I mean, I'm not sure Goldman is intending to make an argument for public healthcare and state-funded medical R&D, but in practice that's what this is.
- OhDagny 9y agoIdeal drug business models mirror the addictive ones. And thus we have an opioid epidemic.
- minikites 9y agoAnd when you run out of patients to cure, just start making up new diseases to treat: https://en.wikipedia.org/wiki/Herpes_simplex#Society_and_culture https://en.wikipedia.org/wiki/Herpes_simplex#Society_and_cul... > Genital herpes simplex was not always stigmatised. It was merely a cold sore in an unusual place until the 1970s. As late as 1975, a study of "Psychological morbidity in a clinic for sexually transmitted disease" does not mention herpes simplex because at that time, no significant morbidity problem (i.e. mental anxiety or illness) was associated with the virus. > Pedro Cuatrecasas states, "during the R&D of acyclovir (Zovirax), marketing [department of Burroughs Wellcome] insisted that there were 'no markets' for this compound. Most had hardly heard of genital herpes..." Thus, marketing the medical condition—separating the 'normal cold sore' from the 'stigmatized genital infection' was to become the key to marketing the drug, a process now known as 'disease mongering'. > Since the creation of the herpes hype, some people experience negative feelings related to the condition following diagnosis, in particular if they have acquired the genital form of the disease. Feelings can include depression, fear of rejection, feelings of isolation, fear of being found out, and self-destructive feelings. These feelings usually lessen over time. Much of the hysteria and stigma surrounding herpes stems from a media campaign beginning in the late 1970s and peaking in the early 1980s. Multiple articles were worded in fear-mongering and anxiety-provoking terminology, such as the now-ubiquitous "attacks", "outbreaks", "victims", and "sufferers". At one point, the term "herpetic" even entered the popular lexicon. The articles were published by Reader's Digest, U.S. News, and Time magazine, among others. A made-for-TV movie was named Intimate Agony. The peak was when Time magazine had 'Herpes: The New Scarlet Letter' on the cover in August 1982, forever stigmatizing the word in the public mind
- Fletcher01 9y agoGOOD NEWS FOR PATIENTS INFECTED WITH HERPES SIMPLEX VIRUS (HSV) AND HIV / AIDS ... read DR. MAGANA is the only traditional doctor who can cure HIV, HERPES SIMPLEX VIRUS 1&2, WART, HEPATITIS including other SKIN INFECTIONS... Using His 21 CURE HERBAL MEDICINE. Recently, a very close friend of mine published an article on how he got rid of his cold sores using the 21 CURE HERBAL MEDICINE by Dr.Magana, which he took for 21 days. I recommend your medicine to people infected or diagnosed with any type of infection. For those who need your contact information, you can simply write to them by EMAIL or WHATSAPP: +2349051208634 maganasolutioncentre@gmail.com PLEASE SHARE WITH FRIENDS AND PEOPLE YOU KNOW WHO NEEDS HELP.
- sebringj 9y agoImagine a corporate AI trained with empathetic traits as its primary goal and with its secondary goal, profits. I wonder if it would decide vaporizing certain individuals at Goldman Sachs would be more empathetic overall to humanity while improving their corporate image and stock evaluation.
- _bxg1 9y agoThis is possibly the most dystopic headline I've ever read.
- ravenstine 9y agoThis might be going a bit off topic, so I apologize if this isn't allowed here, but I recently wrote an article about a chemical used in dental health that was bought by GSK and pulled off the shelves in the United States. I was just reminded by the topic of this post. Because it's an effective product in treating tooth sensitivity(by occluding exposed dentin tubules), but it is also effective in preventing tooth decay when used with fluoride, I can't help but speculate what the motivation was for pulling it off the shelves. https://medium.com/@ravenstine/the-curious-history-of-novamin-toothpaste-620c6bef8881 https://medium.com/@ravenstine/the-curious-history-of-novami... The conspiracy theorist in me wonders if they calculated the potential financial impact in the U.S. of people getting fewer dental caries and realized they'd be making less money overall from related treatments.
- ZeroCool2u 9y agoIf you're interested in this check out Jeffrey Hillman's work at Oragenics[1]. Wired wrote about his work in 2002, which is how I found it[2]. SMarT is the amazing futuristic put dentists out of business almost tech[3], but there's a current 'ProBiotic' consumer version called ProBiora[4] sold as well, however that's a continuous delivery version. Far more profitable it would seem. Unfortunately, they discontinued FDA trials of SMarT for now. 1. https://www.oragenics.com/about/history https://www.oragenics.com/about/history 2. https://www.wired.com/2002/06/better-teeth-through-biochemistry/ https://www.wired.com/2002/06/better-teeth-through-biochemis... 3. https://www.oragenics.com/technology-pipeline/lbp/smart https://www.oragenics.com/technology-pipeline/lbp/smart 4. https://probiorahealth.com https://probiorahealth.com
- jfasi 9y agoHow do we interpret this heartless-sounding statement? In the absence of original source material, whatever interpretation you apply will inevitably be a projection of your pre-existing views on the matter. If you want to knee-jerk your way to the standard "Goldman Sachs is Evil" view, help yourself to the rest of the top-level comments in this thread. If you're still reading, I think I have a worthwhile point to offer: Let's not forget, Goldman Sachs and its biotech brethren are businesses. All business involves long-term strategic planning, often behind closed doors, to answer the question of "what application of our existing money will make us the most money in the future?" When viewed through this lens, Goldman's statement can be polished up to "of all the biotech investment options we're weighing, investment in outright cures for infectious diseases is less profitable in the long-term because curing people has a nonlinear effect on the patient population." It's a simple statement of fact. OP's summary, and I strongly encourage you to actually read it if you haven't, goes on to say that Goldman's research suggests long-term research and product investment would be best applied to medical conditions like cancer and aging, for which a cure for an individual doesn't result in a diminishing market. This isn't nearly as evil-sounding as the article aims to make it sound. At worst, it highlights something we already know: market-based solutions tend to be flawed, and if we want investment in treatments for infectious diseases we need to turn to forces that are exempt from market forces (i.e. government research funding). At best, it's an indication that we can expect more investment to go into things like cancer and age-related diseases.
- danharaj 9y agoThe Goldman Sachs analysts didn't ask an unreasonable question. What are absolutely dismal are the conditions that make it a reasonable question. And what makes them dismal people is that they are totally cool being part of the system that makes such questions reasonable. > In the absence of original source material, whatever interpretation you apply will inevitably be a projection of your pre-existing views on the matter. Literally all interpretation one does about anything is a "projection" of their pre-existing views on the matter.
- Balgair 9y ago> What are absolutely dismal are the conditions that make it a reasonable question I'm a pretty free-market kinda guy, but all systems have flaws. Biotech and capitalism seem to have a fair few chasms between them, and this GS report illustrates one of them quite well. Capitalism is not a 'complete' theory, holes exist in it, as they do in all things. If anything, as the GP states, GS is pointing this one out. Suggestions for what to do about this 'hole in theory' are needed though; likely it's government funding (in a 'lighthouses' manner).
- fadzlishah 9y agoHow is this even a question? It's entirely logical that curing disease effectively decreases the prevalence. Did it really take a big bank to point that out?
- jernfrost 9y agoIt is an excellent example of why health care is fundamentally at odds with capitalism. Now I don’t see this as black and white. The free market is a useful tool one can use in healthcare WHERE it makes sense. However that is not nearly as many places as the conservative free market fan club thinks it is. This ought to be a reminder that more market does not equal better. More market thinking in health care is to the contrary going to bring worse results. It is an extremely difficult problem to solve which means they only way to deal with it is through experimentation, tinkering and data gatering. Not through ideological silver bullets.
- tynpeddler 9y agoThis is such a nothing story. A quote from the article itself: >To get around the sustainability issue overall, the report suggests that biotech companies focus on diseases or conditions that seem to be becoming more common and/or are already high-incidence. It also suggests that companies be innovative and constantly expanding their portfolio of treatments. This can “offset the declining revenue trajectory of prior assets." Lastly, it hints that, as such cures come to fruition, they could open up more investment opportunities in treatments for “disease of aging.” In other words, Sachs is saying that just because you cure a disease, that doesn't mean you can sit on your ass. You have to keep finding diseases to cure. O, the horror.
- sunstone 9y agoHow to win friends and influence people.
- ropable 9y agoI am perfectly cool with health care being a cost center.